MENJAGA: Continuous Quality Improvement for Antenatal HIV, Syphilis and Hepatitis B Testing in Indonesia

Launched by YANRI WIJAYANTI SUBRONTO, MD, PHD, · Sep 22, 2023

Keywords

ClinConnect Summary

The MENJAGA trial is focused on improving the testing and treatment for HIV, syphilis, and hepatitis B among pregnant women in Indonesia. Despite having national guidelines and a good number of women attending prenatal care, many are still not screened for these important diseases. This trial aims to evaluate a new, low-cost approach that encourages local healthcare teams to collect and analyze data to improve their services. By implementing this “Continuous Quality Improvement” method, the hope is to increase the number of pregnant women who get tested and treated for these conditions, ultimately helping to prevent the transmission of these diseases from mothers to their babies.

To participate in this trial, health facilities must meet certain criteria, such as having at least 320 first-time prenatal care visits each year and currently providing testing for these diseases. They should also have a low testing coverage of 30% or less for HIV among pregnant women. Facilities that are already involved in other quality improvement projects or research will not be included. If a facility agrees to take part, they will help implement the new approach and monitor its effectiveness. This trial is an important step towards better healthcare for mothers and their babies in Indonesia.

Gender

ALL

Eligibility criteria

• This is cluster randomized control trial that unit of analysis is health facility. The following are the eligibility criteria for health facilities to be included in the trial:
• • Facility with at least 320 first antenatal care visits or registrations per year (based on previous year's data).
• • Facility is not currently engaged in another quality improvement intervention or other health-related research.
• • Facility expected to provide antenatal care services and HIV/syphilis/hepatitis B testing for the duration of the study.
• • Facility recorded 30% or less coverage of HIV testing amongst pregnant women (based on previous year's data).
• Exclusion Criteria:
• • • If any reason is stated by the facility manager for not implementing the intervention if allocated to the intervention arm. Examples of (non-exhaustive) reasons that would exclude the facility are as follows: refusal to participate because of workload concerns or high turnover of staff, etc.
• • - Facility does not consent to participate